Denmark's Forward Pharma A/S has its sights set on big game, including a massive IPO filing in the U.S. and a potential legal battle with Biogen Idec Inc. It's unclear whether buysiders will view the patent spat as an overhang or an investment opportunity.

Forward Pharma filed last week to raise up to $200 million through the sale of ADSs in its IPO. Leerink Partners is the underwriter.